Navigation Links
Veteran International Health Care Executive Appointed CEO of BeneChill(R)
Date:6/4/2010

SAN DIEGO and STOCKHOLM, June 4 /PRNewswire/ -- Amgen executive Alan Raffensperger has been appointed the new Chief Executive Officer of BeneChill, a privately held medical device company launching its first product, a novel cooling device for use by emergency response teams in the field, later this year in Europe.  With more than 25 years of experience in the pharmaceutical, biotechnology, medical device and diagnostic industries, Mr. Raffensperger joins BeneChill from his post as Executive Director and Franchise Head of Nephrology for Amgen, a global biopharmaceutical company.  He joined Amgen in 2005 as General Manager of the Nordic and Baltic Region, overseeing operations in eight countries from his Sweden base.

(Photo:  http://photos.prnewswire.com/prnh/20100604/LA15970)

(Photo:  http://www.newscom.com/cgi-bin/prnh/20100604/LA15970)

"As we prepare to launch our lead RhinoChill™ product in Europe, it was critical that we recruit a seasoned, well-rounded CEO with big pharma experience and the sensitivity to a smaller company," said Denise Barbut, M.D., Executive Chair and founder of BeneChill. "Alan's stellar track record and experience in product development, sales and marketing will enable us to achieve our business goals."

Prior to Amgen, Mr. Raffensperger was with Hoffman La Roche for ten years with his most recent position as Head of Pharmaceutical Marketing and Sales for Roche in Sweden. Previously, he was the CEO for Swedemed, a privately-held developer of an advanced ultrasonic surgery system. He began his career with Pharmacia, first in sales in the U.S. and then product management in Sweden.

Earlier in his career, Mr. Raffensperger was a paramedic for National Hospital in Arlington, VA and notes that his experience in cardiovascular and trauma emergency care provides a solid foundation for understanding the need for BeneChill's cooling devices in the field.  He received his Bachelor of Science degree in Emergency Health Sciences Management from the University of Maryland and was an MBA candidate at George Washington University.  He is a nationally registered EMT-paramedic.

BeneChill® is a privately held medical device company that develops novel, rapid cooling systems to improve survival after cardiac arrest.  RhinoChill™ can be administered quickly and directly to the brain by a proprietary portable system that uses a nasal catheter to deliver a rapid evaporative coolant and will be marketed in Europe later this year. With corporate headquarters in San Diego, CA, BeneChill will be opening offices in Switzerland.  


'/>"/>
SOURCE BeneChill
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Legion Anticipates Institute of Medicine Report on Gulf War Veterans
2. Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R)
3. MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA
4. Secretary Reinforces VAs Commitment to Research Safety and Veteran Focus
5. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
6. Congresswoman Supporting Spinal Cord Research Intended to Benefit U.S. Veterans
7. NovaRx Appoints Industry Veteran as President and COO
8. For Iraq Veterans, Headaches Continue After Traumatic Brain Injury
9. Algos Attracts CRO Veteran Dr. Ganesh Iyer as its New CEO
10. Biotechnology Salutes Americas Veterans; Innovations Continue to Offer Improved Treatment and Care of Combat Troops
11. FREE Drug Discount Card Saves Money on Prescriptions and Raises Funds for Americas Disabled Veterans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... 20, 2016 According to the 2016 ... increasing demand for affordable healthcare solutions as since the early ... rise. In countries like the US, the healthcare cost rose ... the consumer price index inflation rate stood at an average ... up to 3.62% during the same time period. This can ...
(Date:5/19/2016)... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) announced today that it is ... a chance to meet iconic entertainer Mario Kreutzberger ... past two years has been the face of the company,s ... with type 2 diabetes, which Don Francisco is ... and tips for long-term healthy lifestyle choices. ...
(Date:5/19/2016)... , The data will be presented ... 8006)   The conclusions of the study point to ... with 90% of the m presenting duration ... two percent of the patients had clinical benefit.   ... Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... Backed by decades ... for each job, ensuring the best suited solution to meet regulatory requirements. Their ... at their lab in Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Jonathan (Jon) Otterstatter to its board of directors. Otterstatter is co-founder, president ... the development of technological innovations that lead to broad-based healthcare solutions. , “Jon ...
(Date:5/24/2016)... ... May 24, 2016 , ... WaterAid launched the #perioddrama campaign to mark Menstrual ... 1 billion women around the world who do not have access to a toilet, even ... US about their dread of #perioddrama. The (sometimes hilarious) results help shine a light on ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... patient Services To Begin In June , Aloria Health, specializing in a re-imagined, ... opening of Aloria Milwaukee, its first treatment facility for outpatient, day treatment and ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... tick-borne disease research and education, today announced that it has named Scott Santarella ... the Bonnie J. Addario Lung Cancer Foundation (ALCF) in San Francisco, where he ...
Breaking Medicine News(10 mins):